A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Alemtuzumab (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2018.
- 14 Sep 2016 Status changed from recruiting to active, no longer recruiting.